Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study

Liver International : Official Journal of the International Association for the Study of the Liver
Jun Yong ParkSang Hoon Ahn

Abstract

Sequential therapy posed a high risk of emergence of multidrug resistance and presented a management issue in chronic hepatitis B (CHB) treatment. We evaluated the antiviral efficacy and safety of entecavir (ETV) plus tenofovir (TDF) combination therapy in multidrug-resistant (MDR) CHB patients. In this prospective, multicentre study, MDR CHB patients, defined as measurable serum HBV DNA (≥60 IU/ml) while on any rescue treatment regimen for at least 24 weeks and the presence of documented prior genotypic resistance to both nucleoside analogue(s) and nucleotide analogue, were treated with ETV 1.0 mg and TDF 300 mg combination therapy for 48 weeks. A total of 64 eligible patients who had previously failed to a median three lines of antiviral therapy (range, 2-6) were included. At baseline, median age was 47.0 years, 89.1% were HBeAg(+), and median HBV DNA was 4.24 (range, 2.11-6.73) log10 IU/ml. By week 4, 12, 24 and 48, 15/64 (23.4%), 36/64 (56.3%), 43/64 (67.2%) and 55/64 (85.9%) patients achieved a HBV DNA <60 IU/ml respectively. The mean reduction of HBV DNA from baseline to 4 and 48 weeks was 1.23 log10 IU/ml and 2.38 log10 IU/ml respectively. Although five patients experienced virological breakthrough, all were transient an...Continue Reading

References

Jan 30, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Irene RaptiStephanos J Hadziyannis
Dec 22, 2007·Journal of Hepatology·Giovanna FattovichFrancesco Donato
Mar 13, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Daniel J TenneyRichard J Colonno
Aug 29, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Anna S F Lok, Brian J McMahon
Feb 4, 2012·Journal of Hepatology·Fabien Zoulim, Stephen Locarnini
Feb 14, 2012·The Lancet Infectious Diseases·Robert GishFabien Zoulim
Mar 23, 2012·Journal of Hepatology·UNKNOWN European Association For The Study Of The Liver
Mar 29, 2012·Liver International : Official Journal of the International Association for the Study of the Liver·Chang Young SonJun Yong Park
Oct 18, 2013·Clinical and Molecular Hepatology·Hyung Joon Yim, Seong Gyu Hwang
Dec 18, 2013·Liver International : Official Journal of the International Association for the Study of the Liver·Mi Na KimJun Yong Park
Jun 1, 2012·Hepatology International·Yun-Fan LiawMasao Omata

❮ Previous
Next ❯

Citations

Apr 22, 2017·Journal of Hepatology·UNKNOWN European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, UNKNOWN European Association for the Study of the Liver
Jun 13, 2019·Clinical and Molecular Hepatology·UNKNOWN Korean Association for the Study of the Liver (KASL)
Dec 30, 2020·The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi·Young Eun AhnHyung Joon Yim
May 8, 2020·Antiviral Research·Claire Pierra RouviereJohn E Tavis

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.